| Field | Detail | Source |
|---|---|---|
| Legal name | Paragon Care Limited | FY26 Appendix 4E |
| Trading name | ParagonCare | FY25 Annual Report |
| ABN / ACN | ABN 76 064 551 426 / ACN 064 551 426 | FY26 Appendix 4E; 1H26 Investor Presentation |
| Former names | Not publicly disclosed in reviewed sources (no formal name change identified) | — |
| Founding year (legacy Paragon Care) | 2008 (company "About" page) | paragoncare.com.au |
| Founding year (CH2 / Clifford Hallam lineage) | 1918 ("We started out in Australia in 1918") | FY25 Annual Report |
| Incorporation jurisdiction | Australia (Corporations Act 2001) | FY25 Annual Report, Note 1 |
| Registered office & principal place of business | 77–97 Ricketts Road, Mount Waverley, VIC 3149, Australia | FY25 Annual Report, Note 1 |
| Exchange / ticker | Australian Securities Exchange — PGC (secondary listing: Deutsche Börse ticker PXS, per Fintel) | ASX; Fintel |
| ISIN | AU000000PGC4 | Fintel |
| CUSIP | Not applicable / not publicly disclosed (Australian issuer) | — |
| Fiscal year end | 30 June | Annual reports |
| Employees | 1,292 (FY25); "over 1,200" cited in FY25 Chair/CEO letter; FY24 and FY23 combined-group figures not publicly disclosed | FY25 Annual Report |
| Gender split (FY25) | 51% male / 49% female | FY25 Annual Report |
| Auditor | Ernst & Young (Melbourne; FY25 lead partner Paul Gower) | FY25 Annual Report; FY26 Appendix 4E |
| Share registry | Not re-verified for FY26 (FY22: Link Market Services) | FY22 Annual Report |
| Shares on issue | 1,655,305,389 (weighted average FY25 and FY26; ~1.66bn) | FY26 Appendix 4E, Part 17 |
| Share price (latest verified) | A$0.135 (4 Sep 2026); A$0.13–0.135 range Jul–Sep 2026. | InvestSMART |
| Market capitalisation | ≈A$223m at A$0.135 (1,655.3m shares) | InvestSMART; calculation |
| CEO & MD | Carmen Riley (CEO from 1 Jul 2025; MD from 1 Mar 2026) | ASX announcements 25 Jun 2025, 25 Feb 2026 |
| Chair | Peter Lacaze | FY25 Annual Report |
| Website | https://www.paragoncare.com.au | — |
The entity on the user's list (Paragon Care Limited, ASX: PGC, Australia) remains the same listed legal entity. Its trading name is now styled "ParagonCare". The website on the list (paragoncare.com.au) is current. No change of ticker or exchange has occurred. The economic business, however, is now dominated by the former Clifford Hallam Healthcare (CH2) pharmaceutical wholesale business following the June 2024 reverse acquisition.
ParagonCare is a mid-sized, founder-controlled Asia-Pacific healthcare distributor that combines a high-volume, thin-margin Australian pharmaceutical wholesale engine (inherited from Clifford Hallam Healthcare, Australia's only independent Community Service Obligation wholesaler) with a portfolio of higher-margin specialty businesses: medical technology agencies (imaging, devices, orthopaedics, robotics, vision, aesthetics, dental), third-party healthcare contract logistics, and TGA-certified clinical manufacturing of red-cell blood-bank reagents. FY26 revenue was A$3.68bn, but underlying EBITDA of A$97.2m represents a margin of only ~2.6%, and 96% of revenue still comes from Australia and New Zealand. Strategy is pivoting toward Asia, where six bolt-on acquisitions in FY26 lifted segment revenue 58% to A$160m at ~42% gross margin. The equity story is constrained by a A$38.0m credit loss on the collapsed Infinity Pharmacy Group, a statutory FY26 loss, leverage of ~2.5x, negative net tangible assets, no dividend, and a share price that has fallen roughly 60–70% from its post-merger implied level.
---
### Company's own description
The FY25 Annual Report and FY26 Appendix 4E describe ParagonCare as one of Asia Pacific's leading diversified healthcare distributors and manufacturers, delivering pharmaceuticals, capital equipment, diagnostics, medical consumables, devices and complementary medicines, with origins in Australia in 1918 and a "transformational" 2024 merger of Clifford Hallam and ParagonCare. Its stated purpose is to make healthcare simpler, smarter and more accessible across Asia Pacific, and its vision is to be the region's most trusted and efficient diversified healthcare distribution and manufacturing partner (FY25 Annual Report).
The statutory principal-activities description (FY25 Directors' Report; FY26 Appendix 4E Part 8) is: supply of durable medical equipment, medical devices, consumable medical products and maintenance of technical medical equipment to the health, aged care (and aesthetics/veterinary) markets throughout Australia, New Zealand and Asia, plus distribution of pharmaceuticals, medical consumables and complementary medicines to the Australian healthcare market.
### Go-to-market structure (four channels)
| Channel | Business units | Core customers |
|---|---|---|
| Wholesale | Pharmacy; Medical Consumables; Complementary Medicines (Oborne, ParagonCare Prescribe); Dental Supplies (incl. AHP Dental) | Independent retail pharmacies, non-affiliated and affiliated pharmacy groups (incl. second-line wholesaling), public and private hospitals, aged care, primary care, allied health, naturopaths/TCM practitioners, dental clinics |
| Medical Technology | OEM Capital (imaging, PACS); OEM Devices (infusion, oncology, neonatal, surgical, critical care, urology); Vision; Aesthetics; Surgical Implants/Orthopaedics; Surgical Robotics (CMR Surgical); Service | Public/private hospitals, day surgeries, orthopaedic surgeons, optometrists/ophthalmologists, dermatologists/cosmetic clinics, imaging departments |
| Contract Logistics | 3PL/4PL services for healthcare suppliers (e.g., Owens & Minor from June 2025; Pacific Medical in Hong Kong from Feb 2026) | Pharmaceutical and medtech manufacturers, public health distribution centres, pharmaceutical wholesalers |
| Clinical Manufacturing | Immulab red-cell reagent manufacturing; contract manufacturing (first agreement FY25); diagnostic instruments & consumables distribution; Fisher Biotec (acquired Jan 2026) | Pathology labs, blood banks, IVF clinics, microbiology labs, universities, hospitals |
Following a FY25 restructuring, the group operates through four go-to-market channels supported by shared services (Finance, IT, Marketing, Customer Service, Supply Chain, Commercial, Procurement):
(Source: FY25 Annual Report, "Business Focus" and "Customer Networks" pages; FY26 Results Release.)
### Revenue model and value-chain position
| Revenue type (A$m) | FY25 | FY26 |
|---|---|---|
| Goods (point in time) | 3580.1 | 3652.3 |
| Services (over time) | 33.8 | 28.3 |
| Total revenue | 3613.9 | 3680.5 |
| Supplier rebates (memo) | 417.2 | 450.9 |
The revenue model is overwhelmingly product resale (point-in-time recognition). In FY26, goods transferred at a point in time were A$3,652.3m (99.2%) and services transferred over time were A$28.3m (0.8%), versus A$3,580.1m and A$33.8m in FY25 (FY26 Appendix 4E, Part 9). There is no material subscription or licensing revenue. Supplier rebates are a critical economic lever: rebates of A$450.9m in FY26 (A$417.2m in FY25) offset a gross cost of inventories sold of A$3,787.8m, meaning rebates are larger than the group's entire gross margin (A$347.5m) (FY26 Appendix 4E, Part 9b).
ParagonCare sits in the mid-stream distribution layer of the healthcare value chain: it buys from originator and generic pharmaceutical manufacturers, global medtech OEMs (for which it often holds exclusive regional agency rights) and private-label sources, and sells to pharmacies, hospitals and clinics. Upstream, it manufactures a narrow line of in-vitro diagnostic reagents (Immulab) and offers contract manufacturing. Sideways, it monetises its warehouse network by providing contract logistics to other suppliers.
### Independent characterisation
Economically, ParagonCare is two businesses wearing one ticker:
1. A scale-dependent ANZ pharmaceutical and consumables wholesaler (Wholesale channel ≈A$3.0bn of FY25 revenue, ≈82% of group) operating at a channel margin of ~6.0–6.3% (FY26 Results Release) and ANZ segment margin of ~8.0%, competing against far larger incumbents (EBOS/Symbion, Sigma/Chemist Warehouse, Wesfarmers Health/API). This business generates revenue mass, supplier rebates and CSO funding but very little operating profit after warehouse, freight and finance costs.
2. A specialty distribution and manufacturing portfolio (MedTech ~39–41% channel margin, Clinical Manufacturing ~44–46%, Asia ~42–46%) that likely produces the majority of group gross profit dollars outside wholesale, and which is the explicit focus of capital allocation.
The credit event with Infinity Pharmacy Group (a Priceline franchisee) illustrates the principal structural risk of the wholesale model: very large receivable exposures to individual pharmacy groups relative to the group's thin equity cushion.
### End-markets served
Retail community pharmacy (independent and banner groups), hospital pharmacy (public and private), acute hospitals (capital, devices, implants), aged care and community care, primary care and allied health, dental, aesthetics/dermatology, optometry/ophthalmology, pathology/blood banking, IVF, defence (5-year Australian Defence Force supply contract from Q4 FY26), and B2B logistics for healthcare manufacturers. Geographic end-markets: Australia, New Zealand, Thailand, South Korea, Japan, Philippines, Vietnam, and (via FY26 acquisitions) Singapore, Malaysia, Indonesia, Hong Kong/Macau. The 1H26 presentation cites a presence in nine Asian countries.